9960 Stock Overview
Kindstar Globalgene Technology, Inc., together with its subsidiaries, provides clinical testing services in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Kindstar Globalgene Technology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.56 |
| 52 Week High | HK$1.86 |
| 52 Week Low | HK$1.38 |
| Beta | 0.79 |
| 1 Month Change | 10.64% |
| 3 Month Change | -0.64% |
| 1 Year Change | -11.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.74% |
Recent News & Updates
Recent updates
We Think That There Are More Issues For Kindstar Globalgene Technology (HKG:9960) Than Just Sluggish Earnings
Apr 03
Kindstar Globalgene Technology (HKG:9960) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Aug 22Analysts Just Made A Notable Upgrade To Their Kindstar Globalgene Technology, Inc. (HKG:9960) Forecasts
Aug 18We're Not Very Worried About Kindstar Globalgene Technology's (HKG:9960) Cash Burn Rate
Jul 07Kindstar Global (Beijing) Technology, Inc. (HKG:9960) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 28Shareholder Returns
| 9960 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 2.0% | 6.4% | 3.6% |
| 1Y | -11.4% | -28.6% | -10.1% |
Return vs Industry: 9960 exceeded the Hong Kong Healthcare industry which returned -28.6% over the past year.
Return vs Market: 9960 underperformed the Hong Kong Market which returned -10.1% over the past year.
Price Volatility
| 9960 volatility | |
|---|---|
| 9960 Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 9960 has not had significant price volatility in the past 3 months.
Volatility Over Time: 9960's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 3,125 | Shiang Huang | www.kindstar.com.cn/en/ |
Kindstar Globalgene Technology, Inc., together with its subsidiaries, provides clinical testing services in China. The company offers its esoteric testing services for hematology, genetic diseases, gynecology, infectious diseases, neurology, and oncology diseases. It also provides testing services for the early warning, prevention, diagnosis, selection of therapeutic schedules, and evaluation for curative effect of specialized diseases.
Kindstar Globalgene Technology, Inc. Fundamentals Summary
| 9960 fundamental statistics | |
|---|---|
| Market cap | HK$1.49b |
| Earnings (TTM) | HK$44.60m |
| Revenue (TTM) | HK$1.04b |
33.3x
P/E Ratio1.4x
P/S RatioIs 9960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9960 income statement (TTM) | |
|---|---|
| Revenue | CN¥967.26m |
| Cost of Revenue | CN¥516.13m |
| Gross Profit | CN¥451.13m |
| Other Expenses | CN¥409.84m |
| Earnings | CN¥41.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.043 |
| Gross Margin | 46.64% |
| Net Profit Margin | 4.27% |
| Debt/Equity Ratio | 5.3% |
How did 9960 perform over the long term?
See historical performance and comparison